| Drug Name |
Nelarabine |
| Drug ID |
BADD_D01549 |
| Description |
Nelarabine is an antineoplastic agent that is typically employed to treat acute T-cell lymphoblastic leukemia. Nelarabine is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity. |
| Indications and Usage |
For the treatment of pediatric and adult patients with acute T-cell lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01BB07 |
| DrugBank ID |
DB01280
|
| KEGG ID |
D05134
|
| MeSH ID |
C104457
|
| PubChem ID |
3011155
|
| TTD Drug ID |
D0B8UJ
|
| NDC Product Code |
54893-0118; 70710-1726; 77391-004; 61187-006; 76055-0048; 0078-0683; 43598-142; 70121-1743; 70710-1839; 70771-1685; 71288-165; 81927-111 |
| UNII |
60158CV180
|
| Synonyms |
nelarabine | 2-amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine | 2-amino-6-methoxypurine arabinoside | Arranon | GW506U78 | 506U78 | compound 506U78 |
